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OBJECTIVE—Glucose-dependent insulinotropic polypeptide
(GIP) is a member of a structurally related group of hormones
that also includes glucagon, glucagon-like peptides, and secretin.
GIP is an incretin, known to modulate glucose-induced insulin
secretion. Recent studies have shown that glucagon is necessary
for early insulin-positive differentiation, and a similar role for
incretins in regulating embryonic insulin-positive differentiation
seems probable. Here we studied the role of GIP signaling in
insulin-positive differentiation in the embryonic mouse pancreas.
RESEARCH DESIGN AND METHODS—The ontogeny of the
GIP ligand and GIP receptor in the embryonic pancreas was in-
vestigated by immunohistochemistry and RT-PCR. GIP signaling
was inhibited in cultured embryonic pancreata using morpholine-
ring antisense against GIP ligand and receptor, or small interfering
RNA (siRNA) for GIP ligand and receptor. Markers of endocrine
cells and their progenitors were studied by immunohistochemistry
and RT-PCR.
RESULTS—GIP and GIP receptor mRNA were both detected in
the embryonic pancreas by embryonic day 9.5 and then persisted
throughout gestation. GIP was generally coexpressed with
glucagon by immunostaining. The GIP receptor was typically
coexpressed with insulin. Morpholine-ring antisense or siRNA
against either GIP ligand or GIP receptor both inhibited the
differentiation of insulin-positive cells. Inhibition of GIP or its
receptor also led to a decrease in the number of Pdx-1–positive
and sox9-positive cells in the cultured embryonic pancreas. The
number of Pax6- and Nkx2.2-positive cells, representative of de-
veloping pancreatic endocrine cells and b-cells, respectively, was
also decreased.
CONCLUSIONS—GIP signaling may play a role in early em-
bryonic pancreas differentiation to form insulin-positive cells or
b-cells. Diabetes 60:548–554, 2011
G
lucose-dependent insulinotropic polypeptide
(GIP) is an incretin. Incretins are hormones
released from the gut in response to nutrient
ingestion that potentiate glucose-stimulated in-
sulin secretion (1). GIP and glucagon-like peptide 1 (GLP-1)
are the two main incretins, identiﬁed as mediators of the
process by which administration of oral glucose provokes
a greater stimulation of insulin release than does an
intravenous glucose challenge (2). This connection be-
tween gut and the pancreatic islets has been termed the
“enteroinsular axis” (3) and appears to be responsible for
50% of postprandial insulin release (2,4). GIP is released
from enteroendocrine K-cells in the duodenum, primarily
in response to the ingestion of glucose or fat, and poten-
tiates insulin secretion in a glucose-dependent manner (5).
A recent study now reports the presence of a bioactive
form of GIP in the a-cells that promotes insulin secretion
in the adult islet b-cells (6). GLP-1 is a proglucagon-derived
peptide hormone that is synthesized and secreted by the
enteroendocrine L-cells in the distal ileum and the colon.
Preproglucagon can be alternatively processed to produce
glicentin or oxyntomodulin and GLP-1 (7).
The incretin GLP-1 can enhance b-cell growth and dif-
ferentiation. GLP-1 receptor null mice, however, do not
show a loss of b-cell development. Interestingly, these
mice were found to have upregulated GIP release and GIP-
induced insulin release (8). On the other hand, the GIP
receptor (GIPR) null mice, which also did not show any
obvious b-cell defect, showed enhanced sensitivity to
GLP-1, suggesting that there may be important cooperation
between these two incretin signaling pathways (9).
We and others previously demonstrated that glucagon
signaling to the glucagon receptor is necessary for early
insulin-positive differentiation (10,11). This glucagon de-
pendency also was suggested by the observation that Pax6
or prohormone convertase 2 null mice, which both lack
glucagon-positive cells, also lack early insulin-positive
differentiation (12,13). Although it was reported that GIP is
produced in enteroendocrine K-cells in the duodenum of
the adult, GIP was also found to be produced in the human
fetal pancreas by 18 weeks’ gestation (14). The function of
this GIP in the developing pancreas remains to be eluci-
dated. Here we show that GIP is located in the embryonic
mouse pancreas, and loss-of-function studies in vitro sug-
gest that insulin differentiation in the embryonic pancreas
depends on GIP signaling.
RESEARCH DESIGN AND METHODS
Isolation of embryonic pancreas. All animal experiments were performed in
accordance with the guidelines for animal experimentation of the Children’s
Hospital of Pittsburgh, Pennsylvania. Male and female CD-1 mice were mated
overnight. The presence of a vaginal plug the next morning was indicative of
pregnancy, and noon of that day was designated as embryonic day 0.5 (E0.5).
Embryonic pancreata were harvested on various embryonic days from E9.5 to
E18.5 using microdissection techniques as described previously (15).
Pancreas organ culture conditions. E11.5 pancreata with surrounding
mesenchyme were grown using the hanging drop method by placing them in
a standard 35-mm dish with Dulbecco’s modiﬁed Eagle’s medium F-12 (Gibco
BRL, Grand Island, NY) containing 10% FBS and 1% antibiotic/antimycotic
solution (10,000 units/mL penicillin G, 10,000 units/mL streptomycin sulfate,
and 200 mg/mL amphotericin B [Gibco BRL]). Each drop contains 40 ml media.
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at 37°C for 6 days.
Morpholine-ring antisense. The media containing 20 or 40 mmol/L Mor-
pholino (Gene Tools, Philomath, OR) scrambled missense or antisense for GIP
or GIPR were used with the hanging drop cultures (10). Antisense sequences
to both GIP and GIPR were designed using a 20-bp sequence complimentary to
a sequence spanning the GIP, GIPR, or preproglucagon adenine, thymine,
guanine (ATG) start sequence (5- GGTCTTCATTTTTTATTCTGCCTTG-39)o r
(59-TTTATCACTGTTTGTCTTCTGCTTG-39)( 5 9-GGTCT TCATTTTTTATTCT-
GCCTTG-39), respectively. A 20-bp control oligo sequence for target genes was
designed using randomized nucleotides. Control or antisense treatment was
continued for 6 days, where media was replaced every day with fresh control
or antisense-containing media. Tissues were cultured in 5% CO2 at 37°C for 6
days.
Small interfering RNA. RNA interference was performed with small in-
terfering RNA (siRNA) (16). The siRNA oligonucleotides were synthesized and
puriﬁed by Ambion, which also provided the scrambled negative control.
E11.5 pancreata were transfected with 100 nmol/L siRNA in 1% FBS culture
medium by using the SiPort reagent (Ambion, Austin, TX). After incubation for
24 h, the culture media were replaced with regular siRNA-free culture me-
dium. Media were replaced every day, and pancreata were harvested, ﬁxed,
and processed for histology and immunohistochemistry after 6 days.
Bromodeoxyuridine proliferation assay. Day 11 embryonic pancreata were
treated with control, GIP ligand, or GIPR antisense as described above;
however, after 24 h, 10
25 mol/L bromodeoxyuridine (BrdU) was added to the
culture. The harvested pancreata were ﬁxed in 4% paraformaldehyde over-
night at 4°C, embedded in OCT, and sectioned. The sections were treated with
2 N HCl for 15 min and then with 0.5% Pepsin in 0.1 N HCl for another 15 min
at room temperature. To determine the proportion of proliferating cells, sec-
tions were stained with a BrdU-speciﬁc antibody that will bind to denatured
and acid-degraded BrdU-labeled DNA (Dako, Carpentaria, CA). Cells positive
for BrdU were counted in at least 10 sections obtained from a minimum of ﬁve
pancreata in each group.
Immunohistochemistry. Tissues were ﬁxed in 4% paraformaldehyde in PBS
solution for 6 h. They were then transferred to 30% sucrose in PBS overnight
and then embedded in Tissue Tek OCT compound (Sakura Finetek, Torrance,
CA), frozen in liquid nitrogen, and cut into 6-mm sections using a Microm HM
550 cryostat (Richard-Allan Scientiﬁc, Kalamazoo, MI). Primary antibodies to
the following antigens were used at the indicated dilution: insulin (guinea pig
antiswine; Dako), 1:400; glucagon (rabbit antihuman; Dako), 1:400; a-amylase
(rabbit antihuman; Sigma-Aldrich, St. Louis, MO), 1:400; Pdx-1 (Abcam,
Cambridge, U.K.) 1:2,000; GIP (rabbit antihuman; catalog #T4110; Bachem,
Bubendorf, Switzerland), 1:200; GIPR (rabbit antihuman; Novus Biologicals,
Littleton, CO); Nkx2.2 (mouse antichick; Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IA), 1:5; Pax6 (rabbit antimouse; Co-
vance, Richmond, CA), 1:300; sox9 (Millipore, Billerica, MA), 1:1,000; and
Caspase (Cell Signaling Technology, Danvers, MA), 1:200. Primary antibodies
were incubated at room temperature for 60 min for insulin/glucagon/Pdx-1/
a-amylase and overnight at 4°C for GIP and GIPR. Secondary antibodies,
including ﬂuorescein isothiocyanate–conjugated, AMCA-conjugated, and CY3-
conjugated goat/donkey antirabbit/antiguinea pig/antimouse (Jackson Immu-
noresearch Laboratory, West Grove, PA), were used. Some of the sections were
counterstained with 4’6’-diamidino-2-phenylindole dihydrochloride (DAPI) nu-
clear stain. Images were taken using a ﬂuorescent microscope (Axiostar, Carl
Zeiss, GmbH, Jena, Göttingen, Germany).
Image quantiﬁcation serial sections of pancreas were mounted on slides. On
average, 15–20 sections per pancreas were analyzed for each expressed gene
that was quantiﬁed. Each group had a minimum of three to ﬁve pancreata.
Fluorescent images of sections were scanned at the same magniﬁcation and
exposure conditions. Quantiﬁcation was done with ImageJ software (National
Institutes of Health, Bethesda, MD). First, total area of the pancreas was
measured and then speciﬁc areas were determined on the same section. The
percentage of insulin-speciﬁc area was then determined. Total cell number of
DAPI nuclear staining and percentage of Pdx-1/Pax6/Nkx2.2-positive cells was
quantiﬁed manually. Statistical analysis was done by Student t test or ANOVA.
Data are presented as mean 6 SEM. A P value ,0.05 was considered statis-
tically signiﬁcant.
Isolation of RNA and RT-PCR. Total RNA was isolated from whole pancreas
using the RNeasy kit (Qiagen, Valencia, CA). Isolated RNA was treated with
Promega RQ1 DNase (Promega, Madison, WI) for 1 h at 37°C to remove any
contaminating genomic DNA. Oligo(dt)-primed reverse transcription of RNA
was done for 2 h at 37°C using the Sensiscript Reverse Transcriptase kit
(Qiagen). First-strand cDNA was used as a template for PCR. Optimum re-
action conditions for PCR were obtained with 5 mL1 0 3 PCR buffer (200
mmol/L Tris-HCl [pH 8.4] and 500 mmol/L KCl), 3 mmol/L MgCl2, 0.2 mmol/L
dNTP, 0.025 units AmpliTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA), and 2 mmol/L primers. Ampliﬁcations were performed
starting with a 10-min denaturation step at 95°C, followed by 40 cycles of
denaturation at 95°C for 30 s, 58°C for 40 s for primer annealing, and 72°C for
45 s for extension.
Semiquantitative PCR. Real-time semiquantitative PCR was carried out with
SyberGreen PCR Master Mix in an iCycler iQ apparatus (Bio-Rad, Hercules, CA).
The ampliﬁcation conditions were as follows: 94°C for 5 min, followed by 40
cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s. A mouse b-tubulin
primer set was used to normalize the amount of total cDNA for each gene ex-
pression experiment. Serial concentrations of cDNA (107, 106, 105, 104, 103,
and 102 molecules/mL) were used for the calibration of a standard curve for the
given primer. The PCR products were separated and visualized on the agarose
gel. At least ﬁve different samples were analyzed at each sequential age to
quantify the target gene. Primer sequences used are listed as forward then
reverse, 59 to 39: b-tubulin, 59-CCTTTTGGCCAGATCTTCAG-39 and 59-AACCA-
ACTCAGCTCCCTCTG-39, which amplify a product of 102 bp; GIP, 59-GAGT-
TCCGATCCCATGCTAA-39 and 59-TGTGCCTCTTTGTCCTCCTT-39,w h i c h
amplify a product of 239 bp; and GIPR, 59-CTCATCTTCATCCGCATCCT-39 and
59-GGAAACCCTGGAAGGAACTT-39, which amplify a product of 226 bp.
RESULTS
GIP and GIPR ontogeny in the developing pancreas.
The ontogeny of GIP ligand and GIPR in the developing
pancreas was investigated by immunohistochemistry at
serial gestational days. GIP-positive staining could be
identiﬁed as early as E9.5 and continued through E18.5
(Fig. 1A, C, and E; Supplementary Fig. 1A, E, I, and M).
Pdx-1–positive cells (Supplementary Fig. 1B, F, J, and N)
were present in pancreatic epithelium at early stages and in
b-cells at later stages. Neither of these two Pdx-1–positive
cell populations stained positive for GIP (Supplementary
Fig. 1D, H, L,a n dP). Glucagon-positive staining and
merged images (Supplementary Fig. 1C, G, K, O,a n dD, H,
L, P) revealed that GIP ligand appeared to colocalize with
glucagon, but not with Pdx-1 or insulin (insulin data not
shown). RT-PCR for GIP ligand showed that mRNA ex-
pression of GIP also was present as early as E9.5 and
continued through later gestational stages and into the
postnatal period (Fig. 2A).
FIG. 1. Immunohistochemistry showing the ontogeny of GIP ligand (A,
C,a n dE) and GIPR (B, D, and F). GIP ligand is present in the early
embryonic pancreas, and the expression increases during late gesta-
tional ages. GIPR expression was weak at early ages, but strong ex-
pression was found at later gestational ages (magniﬁcation size bars: A
and B =2 0mmol/L; C and D =5 0mmol/L; E and F = 100 mmol/L).
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GIP mRNA level beginning at E9.5 (Fig. 2C). In situ hy-
bridization was unable to detect GIP ligand, perhaps be-
cause of a low expression level (data not shown). GIP is
a member of a family of structurally related hormones
that includes glucagon and glucagon-like peptides. Thus,
to check for immunostaining cross-reactivity, we pre-
incubated GIP, GLP-1, or glucagon peptide (100 mg/mL)
with GIP antibody or glucagon antibody before immuno-
histochemistry of embryonic mouse pancreas. GIP immu-
nostaining was not inﬂuenced by preincubation with
glucagon peptide or GLP-1 peptide, but was appropriately
blocked by GIP peptide (Supplementary Fig. 2). Similarly,
glucagon immunostaining was not inﬂuenced by pre-
incubation with GIP peptide or GLP-1 peptide, but was
blocked appropriately by glucagon peptide (Supplementary
Fig. 2). Thus, our GIP antibody does not appear to have any
signiﬁcant cross-reactivity with GLP-1 peptide or glucagon
peptide. However, Fujita et al. (6) used a similar antibody
against GIP and found cross-reactivity between GIP and
GLP-1 in adult islet a-cells. The discrepancy between their
results and ours may be due to the use of a different anti-
GIP antibody in the two studies.
Signiﬁcant GIPR staining was not seen until E13.5 and
then continued through E18.5 (Fig. 1D and F). Immuno-
staining for insulin (Fig. 3B, F, J,a n dN), glucagon (Fig. 3C,
G, K, and O), and GIPR (Fig. 3A, E, I, and M) showed that
GIPR expression overlapped primarily with insulin ex-
pression. At E13.5 (Fig. 3H) and E14.5 (data not shown),
many GIPR-positive cells were also positive for either
glucagon or insulin, but by E15.5, the glucagon/GIPR
double-positive cells were not detected (Fig. 3L and P),
and only insulin/GIPR double-positive cells were seen. RT-
PCR for the GIPR showed expression of GIPR mRNA in
early and late developmental and postnatal stages (Fig.
2B). Semiquantitative RT-PCR for GIPR mRNA showed
lower values at days 9–13, followed by a progressive in-
crease in expression over increasing gestational age (Fig.
2D), corresponding roughly to the second wave of b-cell
production, since later-gestation GIPR expression was
only seen in insulin-positive cells.
Inhibition of GIP signaling in the embryonic pancreas
led to decreased insulin-positive differentiation. We
blocked GIP expression in day 11 embryonic pancreas using
different strategies. First, we cultured E11 whole developing
pancreas for 6 days in the presence of Cy3-conjugated
control (GAPDH) siRNA or GIP siRNA (not ﬂuorochrome-
conjugated) at 100 nmol/L. Cy3-conjugated GAPDH siRNA
was successfully incorporated into cultured pancreata
(Supplementary Fig. 3A). There was no obvious gross dif-
ference between pancreata treated with GAPDH siRNA or
with GIP siRNA, as assessed under a dissecting microscope
(Supplementary Fig. 3B and D). Semiquantitative RT-PCR of
GIP mRNA from GIP siRNA-treated E11 embryonic pan-
creas for 6 days in culture showed inhibition of GIP mRNA
expression (Supplementary Fig. 3E). GIP immunostaining
of GIP siRNA-treated pancreas conﬁrmed downregulation
of GIP ligand (Supplementary Fig. 3F and G). The total
GIP-positive staining area was calculated and was found
to be signiﬁcantly decreased with GIP siRNA treatment
(Supplementary Fig. 3H). The area of insulin-positive
staining was calculated by using image analysis software,
and the proportion of the entire pancreas that was insulin
positive was calculated. The total and percentage of insulin
staining area of GIP siRNA-treated cultured pancreas
was signiﬁcantly less than GAPDH siRNA-treated pancreas
(Fig. 4A, E,a n dI). Pdx-1–positive staining (Fig. 4B and F)
was similarly decreased. The proportion of Pdx-1–positive
cells in the pancreas was also signiﬁcantly decreased (Fig.
4J). There was no change in the area of amylase-positive
staining (Fig. 4C and G, quantitation not shown). Semi-
quantitative RT-PCR was performed for insulin and pre-
proglucagon mRNA (Fig. 5A and B), which showed
signiﬁcant decreases in these mRNAs after GIP siRNA
treatment. Pancreatic endocrine precursor cell markers
such as Pax6 and Nkx2.2 were also investigated. Semi-
quantitative RT-PCR analysis showed that both Pax6 and
Nkx2.2 mRNA were signiﬁcantly reduced (Fig. 5C and D).
To conﬁrm, immunohistochemistry for Pax6 and Nkx2.2
was performed on GIP siRNA-treated pancreas, showing
few Pax6- (Supplementary Fig. 4A and B) and Nkx2.2-
positive cells (Supplementary Fig. 4C and D).
FIG. 2. RT-PCR for GIP ligand showed that mRNA expression of GIP was present as early as E9.5 and continued through later gestational stages
and into postnatal stages (A). Semiquantitative RT-PCR showed increasing GIP expression after E9.5 (C). B: RT-PCR of GIPR (GIP Rec) showed
that there was consistent expression of GIPR in early and late developmental and postnatal stages. D: Semiquantitative RT-PCR expression
pattern for GIPR showed low relative values at days 9–13, followed by a progressive increase in expression over increasing gestational age. Error
bars represent SEM.
FUNCTION OF GIP IN EMBRYONIC MOUSE PANCREAS
550 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.orgNext we inhibited GIP signaling by morpholine-ring
antisense as an alternative to siRNA. Pancreases cultured
for 6 days in the presence of 40 mmol/L morpholine-ring
antisense against GIP showed greatly suppressed GIP
expression when compared with Morpholino control
antisense-treated tissues (Supplementary Figs. 5A and B and
6A). GIP Morpholino antisense at 40 mmol/L signiﬁcantly
(P , 0.05) suppressed insulin-positive differentiation
FIG. 3. Immunohistochemical staining for GIPR at serial gestational ages E11.5 (A–D), E13.5 (E–H), E15.5 (I–L), and E18.5 (M–P). Deﬁnite GIPR-
positive staining was ﬁrst identiﬁed at E13.5 and continued through E18.5 (A, E, I,a n dM). Insulin (B, F, J,a n dN), glucagon (C, G, K, and O), and
merged images (D, H, L, and P) are shown. GIPR expression overlapped primarily with insulin. At E13.5, a few glucagon cells also expressed GIPR
(compare 3D and 3H) in addition to the insulin-positive cells that expressed GIPR (magniﬁcation size bars: D and H =2 0mmol/L; L and P =5 0mmol/L).
(A high-quality digital representation of this ﬁgure is available in the online issue.)
FIG. 4. Immunohistochemistry of GIP siRNA-treated embryonic pancreas showed decreased insulin and Pdx-1–positive staining (A, B, E,a n dF).
There was no apparent change in amylase staining (C and G). Area of insulin staining was calculated by using image analysis software, and the
positive proportion of the entire pancreas was then calculated. The insulin-staining area of GIP siRNA-treated cultured pancreas was signiﬁcantly
less than the GAPDH siRNA-treated pancreas (n =3 ,P = 0.003) (I). Pdx-1–positive cells were also signiﬁcantly decreased in GIP siRNA-treated
pancreas (J). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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inhibition, GIP Morpholino antisense treatment also re-
sulted in a signiﬁcant decrease in Pdx-1 (Fig. 6A and B)a n d
Nkx2.2 expression (Fig. 6D and E). sox9-positive cells were
also decreased in GIP ligand antisense-treated samples
(Fig. 6J and K). Interestingly, we did not see any increase
in cleaved caspase staining in GIP ligand antisense-treated
samples, suggesting cells were not undergoing apoptosis
(Fig. 6D and E). We did not detect any signiﬁcant change in
the number of BrdU-positive cells between control and GIP
antisense-treated samples (Fig. 6G and H).
Blocking of GIPR expression in explant cultures in
vitro led to decreased insulin-positive differentiation.
As i g n i ﬁcant decrease in insulin-positive differentiation was
found in embryonic pancreas treated with GIPR morpholine-
ring antisense (Fig. 6C; Supplementary Fig. 5D and E).
The insulin-positive area was signiﬁcantly decreased,
compared with control-treated pancreas (Supplementary
Fig. 7A). Semiquantitative RT-PCR for insulin and gluca-
gon mRNA also showed a signiﬁcant reduction after
40 mmol/L GIPR morpholine-ring antisense treatment
(Supplementary Fig. 7B and C). Pdx-1 and sox9 (markers
of progenitor cells) were also reduced in GIP-receptor
antisense-treated pancreas (Fig. 6C and L). Similar to GIP
ligand antisense, here again after blocking GIP the re-
ceptor, we did not see any signiﬁcant change in apoptosis
(Fig. 6F) or cell proliferation (Fig. 6I).
Similarly, immunohistochemistry after GIPR siRNA
treatment (instead of Morpholino treatment) of cultured
pancreas showed reduced insulin (Fig. 7A–C) and Pdx-1
(Fig. 7A, B,a n dD). Semiquantitative RT-PCR for GIPR
mRNA showed a signiﬁcant reduction of GIPR mRNA after
GIPR siRNA treatment (Fig. 7E), conﬁrming effective
knockdown of expression by the siRNA. Immunohisto-
chemistry of GIPR siRNA-treated pancreas also showed
a signiﬁcant decrease in Pax6- (P = 0.001) and Nkx2.2-
positive (P = 0.0008) cell numbers (Supplementary Fig. 8).
DISCUSSION
GIP and GIPR ontogeny. In mature animals, GIP is syn-
thesized and secreted from intestinal K-cells located mainly
in the duodenum and proximal jejunum. GIP is secreted
in response to nutrient ingestion, especially glucose or fat
(17). GIPR is a member of the seven transmembrane–
spanning, heterotrimeric G-protein–coupled receptor su-
perfamily. In the adult pancreas, GIPR expression can be
seen in the islets (18). However, relatively little is known
about the ontogeny of GIP and GIPR. In our study, GIP
mRNA and protein was found in the developing embryonic
pancreas. The speciﬁcity of the antibody used in this study
was conﬁrmed by peptide preincubation with exogenous
peptides GLP-1, GIP, or glucagon before immunohisto-
chemistry. Our experiments conﬁrmed that GIP is localized
to the developing pancreas, especially in glucagon-positive
cells. Interestingly, beginning at E13.5, GIPR was localized
to insulin-positive cells, consistent with its known presence
in b-cells in the adult (18). There was then a transition from
early GIPR expression before E15.5, when most GIPR-
positive cells were glucagon positive/insulin negative, to later
in gestation, when nearly all GIPR-positive cells were insulin
positive/glucagon negative. These results suggest a possible
paracrine-signaling pathway from glucagon-positive cells to
insulin progenitor cells. Such signaling from glucagon cells to
induce insulin cell formation is supported by studies in which
removal of glucagon or glucagon receptor attenuates early
insulin cell differentiation (10,11,13). Tseng et al. (19) were
unable to detect GIP mRNA in the pancreas of late-gestation
fetal rats. Late gestational pancreas is rife with RNases, and
their lack of detection of what presumably is a low mRNA
copy number for GIP may explain this discrepancy.
GIP signal inhibition in early pancreatic development.
GIPR knockout mice (20,21) did not appear to have pan-
creatic abnormalities that would suggest a developmental
defect. We speciﬁcally studied the embryonic pancreas of
GIPR null mutant mice (a gift from Dr. S. Seino, Osaka,
Japan), which also appeared to be normal (data not
shown). However, these mice are known to exhibit mild
glucose intolerance in response to an oral glucose chal-
lenge. It is possible that this glucose intolerance pheno-
type, as well as a possible embryonic phenotype in GIPR
null mutant mice, is dampened because of compensation
from other signaling pathways, such as GLP-1 signaling.
GIPR null mutant mice have been shown to have enhanced
GLP-1 receptor sensitivity (21). However, GIPR/GLP1-R
double null mutant mice are also born normal, so further
alternative pathways may be in play in the double mutant
FIG. 5. Semiquantitative RT-PCR was performed for insulin and glucagon (A and B, respectively) and showed signiﬁcant decreases of mRNA with
GIP siRNA. Similarly, the Pax6- and Nkx2.2-positive staining areas were decreased signiﬁcantly in GIP siRNA-treated pancreas (C and D). Error
bars represent SEM.
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mice appeared to be due to reduced levels of glucose-
stimulated insulin secretion. Interestingly, GIPR knockout
mice had a normal glucose curve after an intraperitoneal
glucose challenge, suggesting that enteral glucose, with
stimulation of intestinal (K-cell) GIP release, was bypassed
when the glucose was given intraperitoneally.
In our study, siRNA and morpholine-ring antisense
against GIP or GIPR were used to inhibit GIP signaling in
the developing pancreas in vitro. Inhibition of GIP by these
methods resulted in a decrease in insulin-positive differ-
entiation, as well as a decrease in Pdx-1–, Pax6-, and
Nkx2.2-positive cells. Interestingly, we did not see an in-
crease in sox9-positive cells, as we saw in a previous study
where inhibition of ngn-3–mediated endocrine differentia-
tion resulted in a signiﬁcant increase in sox9- and DBA-
positive progenitor cells (22). In addition, we did not see
any obvious change in proliferation or cell death after GIP
or GIPR antisense treatment. Thus, the lack of endocrine
differentiation in these antisense-treated cultures could
represent a failure to differentiate. We have described pre-
viously that inhibition of ngn-3 expression in the embryonic
pancreas led to a signiﬁcant increase in DBA-positive ductal
cells, with several of those cells coexpressing sox-9, sug-
gesting that they may represent expansion of an pancreatic
epithelial progenitor pool (22). Similarly, we also saw an
increase in duct cells in the embryonic pancreas when we
inhibited glucagon signaling using Morpholino antisense
(K.P., C.S., P.G., G.K.G., unpublished data). Similar effects
on an epithelial progenitor cell population may occur after
GIP signaling inhibition.
The discrepancy between our in vitro results and ﬁnd-
ings from genetically altered mice may be due to the
sudden inhibition of GIP signaling that occurs with our in
vitro systems, without the chance for an adaptive response
to compensate for the loss of GIP signaling that may occur
in null mutant mice. This possibility could be tested with
conditional incretin receptor mutants. Counter-intuitively,
GIPR knockout mice have been shown to develop an in-
crease in b-cell area in the adult, perhaps in response to
the oral glucose intolerance mentioned above.
Paracrine GIP signaling from a-cells to b-cells. We
and others previously demonstrated that glucagon is nec-
essary for the early development of insulin-positive cells in
the pancreas because of paracrine actions of glucagon
(10,11). Similarly, our results imply that GIP signaling to
the GIPR is also necessary for early b-cell development.
Such a role for GIP ligand signaling to its receptor is also
suggested by the embryonic localization of GIP and GIPR
in adjacent glucagon- and insulin-positive cells, respectively.
FIG. 6. E11 pancreas cultured for 6 days in the presence of morpholine-ring antisense against GIP, GIPR, or control. Immunohistochemistry was
performed for insulin and Pdx-1 (A, B, and C), Nkx2.2 and caspase (D, E,a n dF), BrdU (G, H, and I), and sox9 (J, K,a n dL). Both ligand and
receptor antisense treatment signiﬁcantly affected endocrine differentiation, as shown by decreased insulin and Nkx2.2 staining (B, C, E, and F).
We also saw a decrease in an undifferentiated progenitor cell population suggested by decreased Pdx-1 and sox9 staining. However, the antisense
treatment did not induce apoptosis (D, E,a n dF) or change the proliferation rate (G, H, and I) (magniﬁcation size bars: 20 mmol/L). (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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insulin secretion and inhibits b-cell apoptosis (4). There,
GIP works via a humoral pathway wherein GIP is rapidly
metabolized by the ubiquitous enzyme, dipeptidyl-pepti-
dase IV (DPPIV) (23), and then the metabolite GIP 3-42 can
work as an antagonist of the GIPR (24). DPPIV can exist as
a soluble form in plasma, or can be attached to the en-
dothelial cell surfaces (25). One possible developmental
pathway that may allow GIP to act in the embryonic pan-
creas is that GIP secreted locally from glucagon-positive
cells in the pancreas may avoid degradation of DPPIV
because of close paracrine signaling to nearby cells. In-
terestingly, our inhibition of GIP signaling led to a decrease
in glucagon-positive cells, both in GIP and GIPR inhibition
studies (Fig. 5B; Supplementary Fig. 5B and E). This loss
of glucagon cells suggests that developing insulin-positive
cells, which are GIPR positive, may normally signal back
to the glucagon-positive cells to maintain these glucagon-
positive cells. Also, immunohistochemistry of the GIPR in
early developing pancreas showed that GIPR was transiently
present in glucagon-positive cells, but then disappeared by
midgestation (Fig. 3H). This expression pattern suggests
that GIP could also work in an autocrine manner in a-cell
development early in pancreatic development.
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